Skip to main content

Find Clinical Trials

Home
Conditions
Lymphoma, T-Cell

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

694 public trials 105 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Recruiting

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

NCT07523555

Conditions: BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blood Protein Disorders, +50 more
Locations: Peking University Shenzhen Hospital Shenzhen, Guangdong, China

View Trial Details

Recruiting

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

NCT07525466

Conditions: Extranodal NK T Cell Lymphoma, Hemic and Lymphatic Diseases, Hemophagocytic Lymphohistiocytosis (HLH), +10 more
Locations: Beijing Tongren Hospital, Capital Medical University Beijing, China

View Trial Details

Recruiting

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations: Universitair Ziekenhuis Gent (UZ Gent) Ghent, Belgium

UZ Leuven - Gasthuisberg Campus Leuven, Belgium

Vseobecna fakultni nemocnice Prague, Czechia

Aarhus University Hospital Aarhus, Denmark

View all 44 locations

View Trial Details

Recruiting

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

NCT05544968

Conditions: CD30+ Anaplastic Large Cell Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, +19 more
Locations: Froedtert & the Medical College of Wisconsin Milwaukee, Wisconsin, United States

View Trial Details

Recruiting

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

NCT03587844

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations: Stanford University Medical Center Stanford, California, United States

Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen Montvale, New Jersey, United States

View Trial Details

Recruiting

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma

NCT04512534

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Dongmei Ji Shanghai, Shanghai Municipality, China

View Trial Details

Recruiting

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

NCT07047885

Conditions: Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Moffitt Cancer Center Tampa, Florida, United States

View Trial Details

Recruiting

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

NCT07300514

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoblastic Lymphadenopathy, +11 more
Locations: Fudan University Shanghai Cancer Center Shanghai, China

View Trial Details

Recruiting

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT06519526

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Fudan University Shanghai Cancer Center Shanghai, China

View Trial Details

Recruiting

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

NCT07164560

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations: 2nd Affiliated Hospital,School of Medicine,Zhejiang University Hangzhou, Zhejiang, China

View Trial Details